Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from post-hoc analyses of its PROMISE-1 and PROMISE-2 Phase 3 clinical trials for eptinezumab, an investigational monoclonal antibody developed for the prevention of migraine.
Detailed data will be shared at the American Headache Society’s (AHS) 61st Annual Scientific Meeting in Philadelphia that further support eptinezumab’s clinical profile, including data on migraine-free months, migraine severity and quality of life.
‘These new data analyses further validate our belief that, if approved, eptinezumab can provide clinically meaningful improvements for people living with migraine, which is considered the most disabling disease of people in the most productive years of their lives,’ said Roger K. Cady, M.D., vice president, neurology of Alder BioPharmaceuticals. ‘With these new data showing the clinical effects of rapid, robust and sustained suppression of CGRP, we are excited about the potential of eptinezumab to be a compelling new treatment option for migraine prevention.’
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.